A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations

Inclusion Criteria: * Histologically confirmed diagnosis of advanced/metastatic microsatellite stable colorectal cancer with KRASG12C mutation with 1+ prior line(s) of therapy * Confirmed KRASG12C mutation status. If a molecular profiling report is not available, a representative paraffin-embedded tumor block or a minimum of 10 unstained slides will be requested for retrospective KRASG12C mutation testing. * Unresectable or metastatic disease. * Participants must have received at least one prior line of chemotherapy for metastatic disease with progression on treatment or intolerance to therapy. * Presence of measurable disease per RECIST 1.1 * Willingness to participate in on-study related procedures, including mandatory biopsies (one baseline and one on-treatment biopsy). * Age ≥ 18 years. Because no dosing or adverse event data are currently available on the use of the proposed combination in patients \<18 years of age, children are excluded from this study. * Able to take oral medications. * Most recent prior systemic therapy (e.g., chemotherapy, immunotherapy or investigational agent) and radiation therapy discontinued at least 7 days before first dose. * Recovery from the treatment-related adverse effects of prior therapy at the time of enrollment to ≤ Grade 1 (excluding alopecia and prior oxaliplatin-induced neuropathy). * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Laboratory values within the screening period: * Absolute neutrophil co…